Hogan Lovells represents Gilead Sciences and Kite Pharma in collaboration and license agreement with oNKo-innate Pty. Ltd.
Press releases
| 24
April
2020
Northern Virginia, 24 April, 2020 – Hogan Lovells represented biopharmaceutical companies Gilead Sciences and Kite Pharma in their cancer immunotherapy research collaboration with oNKo-innate Pty. Ltd. to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.
Under the collaboration, oNKo-innate will execute screens to identify and validate targets to seed internal Gilead immuno-oncology discovery programs, and will create and evaluate NK constructs for Kite’s development of next-generation cell therapies.
The Hogan Lovells team advising Gilead and Kite included Northern Virginia partner Cullen Taylor, Washington, DC partner Adam Bellack, and Northern Virginia associate Rachel Eisen.